Inside the research
Moderna, Inc.
MRNA Research profile · latest available data
Price overview
$198.88
▲ +4.06 (+2.1%)
| 52w hi | $198.88 |
|---|---|
| 52w lo | $22.36 |
| Vol | 13.90M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.01
| Short | +0.24 |
|---|---|
| Medium | +0.14 |
| Long | -0.69 |
computed 2026-09-27
Key fundamentals
Moderna, Inc.
Healthcare · Biotechnology
| Market cap | $79.40B |
|---|---|
| Enterprise value | $75.55B |
| Forward P/E | -44.50x |
| EV / EBITDA | -34.42x |
| P / S (ttm) | 35.64x |
| Profit margin | -141.4% |
| Return on equity | -39.0% |
| Revenue growth | +2.1% |
| Debt / equity | 19.04 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | -0.22 | |
| Sector | +0.13 | |
| Technical | +0.14 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Risk Metrics
| Beta vs SPX | 1.53 |
|---|---|
| Corr SPX | 0.17 |
| Annual vol | 144.0% |
| Annual ret | +118.4% |
| Sharpe | 0.82 |
| Max DD | -66.5% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $43.37 |
|---|---|
| High / Low | $69.00 / $21.00 |
| Median | $45.00 |
| Analysts | 19 |
| Strong Buy | 2 | |
|---|---|---|
| Buy | 2 | |
| Hold | 16 | |
| Sell | 1 | |
| Strong Sell | 2 |
Recent rating actions
| 2026-05-04 | UBS | → Neutral |
| 2026-05-04 | RBC Capital | → Sector Perform |
| 2026-05-04 | Goldman Sachs | → Neutral |
| 2026-05-04 | Evercore ISI Group | → In-Line |
| 2026-04-02 | Barclays | → Equal-Weight |
| 2026-02-23 | Piper Sandler | → Overweight |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-07-31 | Earnings Release, Exhibits | read |
| 2026-07-08 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-05-11 | Bylaws Amendment, Shareholder Vote… | read |
| 2026-05-01 | Earnings Release, Exhibits | read |
| 2026-03-05 | Material Agreement | read |
| 2026-02-13 | Earnings Release, Exhibits | read |
| 2026-02-11 | Reg FD Disclosure, Other Material Event… | read |
| 2026-01-12 | Earnings Release, Reg FD Disclosure… | read |
| 2026-01-05 | Reg FD Disclosure, Exhibits | read |
| 2025-11-24 | Material Agreement, Material Obligation… | read |
| 2025-11-20 | Reg FD Disclosure, Exhibits | read |
| 2025-11-13 | Shareholder Vote | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-06 | Bancel Stephane | Chief Executive Officer | Option exercise | 252.47K | $4.83M |
| 2026-08-05 | Bancel Stephane | Chief Executive Officer | Option exercise | 499.25K | $9.56M |
| 2026-08-05 | Bancel Stephane | Chief Executive Officer | Sell | 187.04K | $11.00M |
| 2026-08-05 | Bancel Stephane | Chief Executive Officer | Sell | 147.47K | $8.29M |
| 2026-08-05 | Bancel Stephane | Chief Executive Officer | Sell | 39.89K | $2.32M |
| 2026-08-05 | Bancel Stephane | Chief Executive Officer | Sell | 124.84K | $7.11M |
| 2026-07-15 | Hoge Stephen | President | Option exercise | 16.11K | $308.51K |
| 2026-07-15 | Hoge Stephen | President | Sell | 53.34K | $3.61M |
| 2026-07-15 | Hoge Stephen | President | Option exercise | 37.23K | $712.88K |
| 2026-07-02 | Mock James M | Chief Financial Officer | Option exercise | 1.45K | — |
Flow & Concentration
| Insider 180d net | -$35.23M |
|---|---|
| Insider buys / sells | 0 / 7 |
| Insider bias | Sellers |
| 13F holders | 8 |
| Top-5 share | 99.4% |
| HHI | 4,667 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| Fidelity / FMR LLC | $3.63B | 51.86M |
| State Street Corp | $1.10B | 15.73M |
| Citadel Advisors | $436.46M | 6.23M |
| Capital Research / Capital World | $361.90M | 5.17M |
| Millennium Management | $51.03M | 728.72K |
| AQR Capital Management | $33.55M | 479.14K |
| Bridgewater Associates | $807.24K | 11.53K |
| T. Rowe Price Group | $391.44K | 5.59M |
As of 2026-06-30
SEC Filings
The Long Run
FY 2018–2025 · 8 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $1.94B | +51.0% | |
| Operating income | -$3.07B | +41.1% | |
| Net income | -$3.56B | — | |
| Cash from ops | -$3.12B | +193.9% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $195.35 | $202.67 | $192.51 | $198.88 | 13.90M |
| Sep 24 | $180.60 | $195.71 | $180.39 | $194.82 | 16.61M |
| Sep 23 | $183.40 | $192.31 | $181.30 | $182.11 | 17.73M |
| Sep 22 | $168.50 | $187.20 | $168.30 | $182.56 | 24.03M |
| Sep 21 | $161.05 | $176.86 | $159.06 | $172.94 | 21.02M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →